James E. Talmadge

Subjects

Antineoplastic Agents, Antineoplastic agents, Biological Response Modifier Program (U.S.), Biological products, Biological response modifiers, Cancer, Cancer, immunological aspects, Drug Screening, Immune response, Immunologic Adjuvants, Immunological aspects, Immunological aspects of Cancer, Immunology, Immunotherapy, Methods, Neoplasms, Preclinical Drug Evaluation, Regulation, Testing, Therapeutic use, Therapy